Article
San Francisco - Topical immunomodulators, specifically imiquimod 5 percent cream (Aldara), may be a viable option for treating patients with invasive squamous cell carcinoma (SCC) or aggressive basal cell carcinoma (BCC) who are no longer candidates for surgery, said Ulrich Hengge, M.D.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.